Trials / Terminated
TerminatedNCT04990440
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV Doses of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of Bermekimab, compared with placebo, in participants with moderate-to-severe atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bermekimab | Participants will receive bermekimab IV. |
| DRUG | Placebo | Participants will receive placebo IV. |
Timeline
- Start date
- 2021-09-02
- Primary completion
- 2022-03-09
- Completion
- 2022-03-09
- First posted
- 2021-08-04
- Last updated
- 2023-05-24
- Results posted
- 2023-05-24
Locations
11 sites across 2 countries: United States, Argentina
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04990440. Inclusion in this directory is not an endorsement.